Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy
Journal of Surgical Oncology, cilt.73, sa.1, ss.12-16, 2000 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 73 Sayı: 1
- Basım Tarihi: 2000
- Dergi Adı: Journal of Surgical Oncology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.12-16
- Anahtar Kelimeler: doxorubicin, ifosfamide, soft tissue sarcoma, HIGH-DOSE IFOSFAMIDE, ADVANCED REFRACTORY SARCOMAS, PHASE-II TRIAL, PLUS DOXORUBICIN, EUROPEAN-ORGANIZATION, ADRIAMYCIN, MESNA, ADULT, BONE, INFUSION
- Lokman Hekim Üniversitesi Adresli: Hayır
Özet
Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas. Forty consecutive patients with a median age of 35.5 years were treated. Ifosfamide was administered at a dose of 2.5 g/m2/day as 72-hour continuous infusion with mesna at the same dosage and schedule. Doxorubicin was given at the dose of 60 mg/m2/day as 2-hour infusion on day 1. Six patients had a complete response (15%), and 9 (22.5%) had a partial response, fourteen patients (35%) stable disease, and 11 (27.5%) did not respond to chemotherapy. The median duration of response was 13 and 5 months for the complete and partial responders, respectively. The median survival was 37 months. Febrile neutropenia was encountered in 9 cases (22.5%). The present ifosfamide and doxorubicin combination is a moderately effective and well- tolerable regimen in the treatment of advanced soft tissue sarcomas.